Sickle Cell Disease Archives - Page 2 of 3 - MPR

Sickle Cell Disease

MPR Weekly Dose Podcast: Episode 15

Back from our Thanksgiving break, this week we talk about the new approval for sickle cell disease; the re-introduction of a product that was taken off the market in the 60’s; The first ready-to-use phenylephrine injection; A new ultrasound enhancing agent; And an approval for arthritis.

MPR Weekly Dose Podcast: Episode 14

This week on the Pod we talk about the FDA Advisory Committee vote on Vascepa; Antibiotic resistant threats; New contact lenses approved to slow myopia in children; A new treatment for sickle cell disease; And an approval for the rare disease, acute hepatic porphyria.

Crizanlizumab Granted Priority Review for Sickle Cell Pain Crises Prevention

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for crizanlizumab (SEG101; Novartis) for the prevention of vaso-occlusive crises in patients with sickle cell disease. Crizanlizumab is an investigational humanized monoclonal antibody that blocks P-selectin mediated multicellular adhesion; P-selectin is a major driver of the vaso-occlusive process in…